A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

Multiple Sclerosis Clinical Trial

— SATURATE-MS  

Official title:

End of Dose Phenomena in Subcutaneous Natalizumab Treated MS Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05701423
• Other study ID #: DE-TYS-12185
• Status: Active, not recruiting
• Start date: February 8, 2023
• Est. completion date: July 31, 2024

Study information

• Verified date: June 2024
• Source: Biogen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary objective of this study is to better understand the pathophysiological background of end-of-dose symptoms (EOD) and thereby determine the percentage of participants who develop EOD under natalizumab (NTZ) as an example of interval therapy in MS and to detect specific changes through multimodal analyses, including radiological, blood and digital health measurements, that may be used as potential biomarkers in the future to map EOD.

Description:

Participants will additionally be offered to record daily activity and sleep patterns as well as heart rate for the duration of the study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 34
• Est. completion date: July 31, 2024
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Diagnosed Relapsing-Remitting Multiple Sclerosis (RRMS) according to 2017 revised McDonald criteria
• Initiation of treatment with SC NTZ according to summary of product characteristic (SmPC) and in accordance to national guidelines or
• Continuing treatment with IV NTZ
• Owns and be able to handle a smartphone

Key Exclusion Criteria:

• Participants with an acute MS relapse and/or a history of intravenous corticosteroid treatment within past six weeks
• Any comorbidity resulting in an impairment to understand or successfully complete the study such as (but not restricted to) psychiatric comorbidities or dementia
• Diagnosis of primary or secondary progressive MS
• Additional immunosuppression except of natalizumab NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• Natalizumab
Administered as specified in the treatment arm.

Locations

Country	Name	City	State
Germany	Klinik für Neurologie, Universitätsklinikum Düsseldorf	Düsseldorf

Sponsors (1)

Lead Sponsor	Collaborator
Biogen

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants who Develop End of Dose Symptoms (EOD) Under NTZ		Up to 30 weeks
Secondary	Change From Baseline in Expanded Disability Status Scale (EDSS) Score	The EDSS is used to quantify disability due to symptoms of MS and to track changes in disability status over time. Scores range from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). Higher scores indicate the worse level of disability.	Baseline up to 30 weeks
Secondary	Change From Baseline in Fatigue Scale for Motor and Cognitive Functions (FSMC)	Fatigue is rated using the self-administered 20-item FSMC questionnaire that includes ten questions related to motor fatigue and ten questions related to cognitive fatigue. A Likert-type 5-point scale (ranging from 'does not apply at all' to 'applies completely') produces a score between 1 and 5 for each scored question. Minimum value is 20 (no fatigue at all) and maximum value is 100 (severe fatigue). Higher scores indicate higher fatigue.	Baseline up to 30 weeks
Secondary	Change From Baseline in Fatigue Severity Scale (FSS)	The FSS is a self-assessment questionnaire that provides a score as a measurement of the severity of fatigue. It consists of 9 questions scored from 1 to 7, low value indicates strong disagreement with the statement, whereas a high value indicates strong agreement. A total score of 36 or more suggests the presence of fatigue.	Baseline up to 30 weeks
Secondary	Change From Baseline in World Health Organization Quality of Life Brief Version (WHOQOL-BREF) Score	The WHOQOL-BREF questionnaire measures quality of life across 4 domains: Physical health, psychological health, social relationships and environment. It also includes one question on overall QOL and one on general health. The WHOQOL-BREF scores correlate highly (.89 or above) with WHOQOL-100 scores, and demonstrate good discriminant validity, content validity, internal consistency and test-retest reliability. The four WHOQOL-BREF domain scores will be used as main outcome measure. The measure is calculated by summing the point values for the questions corresponding to each domain and then transforming the scores to a 0-100 point interval, higher score correspond to greater QOL.	Baseline up to 30 weeks
Secondary	Change From Baseline in Brief Fatigue Inventory (BFI) Score	A questionnaire will be used to measure the severity of fatigue in the past 24 hours. This 9-item self-reported questionnaire is scored on a 0-10 numerical rating scale, where 0 and 10 represent absence and the highest severity of fatigue, respectively.	Baseline up to 30 weeks
Secondary	Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score	MSFC has 2 components: Timed 25-foot walk (T25FW) and 9-hole peg test (9HPT) [dominant and nondominant hands]. The MSFC Z-score is calculated by creating Z-scores for each component of the MSFC and averaging them to create an overall composite score. MSFC Z-score = (Z25-foot-walk + Z9HPT-2)/2, where Zj refers to Z-scores of component j. A Z-score represented the number of standard deviations participant's test result was higher (Z >0) or lower (Z <0) than the average test result (Z = 0) from the reference population. Higher scores indicate better outcomes.	Baseline up to 30 weeks